Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis
Gail P. Risbridger(Monash Institute of Medical Research), Damien Bolton(University of Melbourne), David Clouston(TissuPath), J.K. Pedersen(TissuPath), Roxanne Toivanen(Columbia University), Ania Sliwinski(Peter MacCallum Cancer Centre), Mark Frydenberg(Monash University), Renea A. Taylor(Monash University), Sally M. Hunter(The Royal Melbourne Hospital), David Pook, Hong Wang(National University of Singapore), Jason Li, Declan G. Murphy(University of Melbourne), Heather Thorne(University of Melbourne), Mitchell G. Lawrence(Prostate Cancer Foundation of Australia), Gillian Mitchell(Peter MacCallum Cancer Centre), Melissa Papargiris(Monash University)
Cited by 137
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k